EWA
ANIP icon

EverSource Wealth Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

EverSource Wealth Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.3K Buy
64
+3
+5% +$241 ﹤0.01% 3255
2026
Q1 		$4.69K Hold
61
– – ﹤0.01% 3296
2025
Q4 		$4.82K Hold
61
– – ﹤0.01% 3138
2025
Q3 		$5.59K Buy
61
+3
+5% +$245 ﹤0.01% 3110
2025
Q2 		$3.79K Buy
58
+41
+241% +$2.67K ﹤0.01% 3274
2025
Q1 		$1.14K Buy
17
+10
+143% +$597 ﹤0.01% 3182
2024
Q4 		$387 Buy
+7
New +$402 ﹤0.01% 3276

Other funds holding ANIP

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
MMA
Mizuho Markets Americas New York $6.37B AUM 47.14% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
RL
Ruffer LLP London, United Kingdom $2.83B AUM 30.34% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM

EverSource Wealth Advisors's ANIP Position: Q2 2026 in Review

EverSource Wealth Advisors increased its ANI Pharmaceuticals (ANIP) stake by 4.9% in Q2 2026, buying an estimated $241 and bringing the position to 64 shares worth $5.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3255.

EverSource Wealth Advisors first reported a position in ANIP in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.59K in Q3 2025. 79 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • EverSource Wealth Advisors held 64 shares of ANI Pharmaceuticals worth $5.3K as of Q2 2026.
  • EverSource Wealth Advisors bought 3 ANI Pharmaceuticals shares in Q2 2026, an estimated $241.
  • ANI Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3255 holding.
  • EverSource Wealth Advisors first reported a position in ANI Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • EverSource Wealth Advisors's ANI Pharmaceuticals position peaked at $5.59K in Q3 2025.
  • 79 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.